Hypertension during treatment is common among adolescents and young adults (AYAs) being treated with vascular endothelial growth factor (VEGF) inhibitors for renal cancer, according to a study published online July 5 in the ...
Jul 26, 2023
0
0
Despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo, according to a study in the July 2 issue of JAMA.
Jul 1, 2014
0
0
Treatment with the drug sorafenib as a third or fourth line therapy does not result in improved overall survival among patients with advanced non-small cell lung cancer (NSCLC), according to findings released at the ESMO ...
Sep 29, 2012
0
0
The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial, which will be presented today by a researcher ...
Jun 2, 2013
0
0
Adding radiation therapy to systemic therapy for patients with advanced liver cancer can extend overall survival and delay tumor progression without compromising patients' quality of life, a randomized phase III clinical ...
Oct 24, 2022
0
2
New results from phase III trials exploring treatment options for patients with advanced renal cell carcinoma were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.
Oct 1, 2012
0
0
(HealthDay)—The cancer drug sorafenib, known by its trade name Nexavar, could have a toxic effect on the pancreas of patients who take it for extended periods.
Oct 9, 2013
0
0
In results presented at ASCO 2013, a University of Colorado Cancer Center study provides important details for a recently identified driver and target in lung adenocarcinoma: rearrangement of the gene RET. The finding is ...
Jun 3, 2013
0
0
Hepatocellular carcinoma (HCC) is the most common form of liver cancer and results from long-term damage and fibrosis, such as is caused by chronic alcohol abuse and viral-induced hepatitis. Patients with advanced HCC are ...
Jul 21, 2016
0
0
Results from a recent preclinical study have shown that a new drug combination therapy being developed at Virginia Commonwealth University Massey Cancer Center effectively killed colon, liver, lung, kidney, breast and brain ...
Nov 5, 2013
0
0
